CUE – cue biopharma, inc. (US:NASDAQ)
Stock Stats
News
Cue Biopharma (NASDAQ:CUE) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.
Cue Biopharma (NASDAQ:CUE) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.
Singapore-based ImmunoScape Pioneers Next-Generation Cell Therapy for Solid Tumors; Announces Key Licensing Deal, New Board and SAB Appointments [Yahoo! Finance]
Singapore-based ImmunoScape Pioneers Next-Generation Cell Therapy for Solid Tumors; Announces Key Licensing Deal, New Board and SAB Appointments
Cue Biopharma GAAP EPS of -$0.07 beats by $0.02, revenue of $2.15M misses by $0.14M [Seeking Alpha]
Form 4 Cue Biopharma, Inc. For: Sep 29 Filed by: Warren Lucinda
Form 4 Cue Biopharma, Inc. For: Sep 29 Filed by: Baker Daniel G.
Form 8-K Cue Biopharma, Inc. For: Nov 24
Form 8-K Cue Biopharma, Inc. For: Nov 17
Form 10-Q Cue Biopharma, Inc. For: Sep 30
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.